Bizarre Patents
Smoking Cessation Lighter and Method
A lighter for tobacco products suppresses the urge to smoke by operant conditioning.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20100256063 | Method for Increasing Cardiac Mass and Performance The present invention relates to methods of using a proline/arginine-rich peptide such PR11 or PR39 for increasing cardiac mass or performance and in the treatment of heart failure.... | 10/07/2010 |
| 20100240589 | DIASTEREOMERIC PEPTIDES USEFUL AS INHIBITORS OF MEMBRANE PROTEIN ASSEMBLY The present invention relates to membrane binding diastereomeric peptides comprising amino acid sequences corresponding to a fragment of a transmembrane proteins, wherein at least two amino acid residues of the diastereomeric peptides being in a D-isomer configuration. ... | 09/23/2010 |
| 20100234304 | BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING There is described a material comprising tapes, ribbons, fibrils or fibres characterized in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a β-sheet tape-like substructure.... | 09/16/2010 |
| 20100234305 | POLYMERIC DELIVERY FORMULATIONS OF LEUPROLIDE WITH IMPROVED EFFICACY The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The ... | 09/16/2010 |
| 20100234303 | AGENTS, METHODS AND USES The present invention relates to agents, compositions and methods for use in medicine. In particular, the invention relates to agents related to GnRH peptides.... | 09/16/2010 |
| 20100233095 | CONFORMATIONALLY DYNAMIC PEPTIDES Disclosed are novel peptides that are useful, for example, for detecting target proteins having a β-sheet secondary structure which may be associated with a disease, and for diagnosing and treating such a disease. Related methods and kits also are disclosed.... | 09/16/2010 |
| 20100233161 | NOVEL MULTIFUNCTIONAL COMPOUNDS FOR PHARMACEUTICAL PURPOSES The invention relates to a synthetic bifunctional non-antibody compound comprising one or more effector moieties and one or more binder moieties, wherein the effector moieties are operably linked to the binder moieties via a linker, the effector moieties are ligands to ... | 09/16/2010 |
| 20100233262 | COATED TABLET A main object of the present invention is to provide a novel coated tablet which contains a drug having a guanidino group and does not suffer an obvious color change even when packed in a one-dose pack together with a drug having a (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl... | 09/16/2010 |
| 20100226969 | COMPOUNDS FOR INHIBITING PROTEIN AGGREGATION, AND METHODS FOR MAKING AND USING THEM The invention provides compositions comprising protein aggregation inhibitors, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for preventing, reversing, slowing or inhibiting protein aggregation, e.g., for treat... | 09/09/2010 |
| 20100226916 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND CONDITIONS The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiog... | 09/09/2010 |
| 20100227816 | Use of GLP-1 Analogues for the Treatment of Disorders Associated with Dysfunctional Synaptic Transmission The present invention relates to a peptide analogue of glucagon-like peptide-1 (7-36), which is useful to prophylactically prevent, improve, or reverse the diminished cognitive function associated with these types of disorders, by increasing (or sustaining) the LTP of s... | 09/09/2010 |
| 20100226954 | POLYMERIC DELIVERY FORMULATIONS OF LEUPROLIDE WITH IMPROVED EFFICACY The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The ... | 09/09/2010 |
| 20100227824 | PHARMACEUTICAL PEPTIDES FOR THE TREATMENT OF INFLAMMATORY DISEASES The invention provides pharmaceutical compositions comprising at least a portion of a chemokine receptor or a G-protein coupled receptor. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune ... | 09/09/2010 |
| 20100222550 | Compstatin analogs with improved activity Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nu... | 09/02/2010 |
| 20100222255 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used fo... | 09/02/2010 |
| 20100221251 | Compositions and Methods for Treatment of Cancer The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquino... | 09/02/2010 |
| 20100221242 | ANTI-VIRAL GRIFFITHSIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE A method of inhibiting a viral infection of a host comprising administering to the host an anti-viral griffithsin polypeptide comprising SEQ ID NO: 3 or a fragment thereof comprising at least eight contiguous amino acids, a nucleic acid encoding the anti-viral polypepti... | 09/02/2010 |
| 20100222280 | PEPTIDES WITH THE CAPACITY TO BIND TO TRANSFORMING GROWTH FACTOR beta 1 (TGF-beta 1) The described peptides possess the capacity to bind to Transforming Growth Factor TGF-β1 (TGF-β1), and are potential inhibitors of the biological activity of TGF-β1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pa... | 09/02/2010 |
| 20100221211 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE The invention relates to a compound of general formula (I-0): wherein R1 means a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, or a C3-C6 cycloalkyl group; R2, R3... | 09/02/2010 |
| 20100216720 | ANTIBODIES TO TROPONIN I AND METHODS OF USE THEREOF The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syn... | 08/26/2010 |
| 20100216723 | NEUROPROTECTION USING NAP-LIKE AND SAL-LIKE PEPTIDE MIMETICS This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disea... | 08/26/2010 |
| 20100216701 | Protein Kinase C Inhibitors for Prevention of Insulin Resistance and Type 2 Diabetes The present invention provides peptides and peptide analogs capable of inhibiting the activity of protein kinase C. The invention discloses use of such peptides and analogs for preparation of pharmaceutical compositions and methods for prevention, delay, suppression or ... | 08/26/2010 |
| 20100216716 | Cell-Permeable Peptide Inhibitors Of The JNK Signal Transduction Pathway The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.... | 08/26/2010 |
| 20100215676 | KDR PEPTIDES AND VACCINES COMPRISING THE SAME The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and p... | 08/26/2010 |
| 20100215591 | ANTIMICROBIAL PEPTIDE, COMPOSITIONS, AND METHODS OF USE The present invention provides antimicrobial peptides that exhibit a broad range of antimicrobial activity to gram positive and gram negative bacteria, as well as fungi, mold, and virus. The antimicrobial peptide of the invention is a cationic peptide, and may contain a... | 08/26/2010 |
| 20100210528 | Compositions, methods and uses for inhibition and/or treatment of influenza infection Embodiments of the present invention illustrate methods and compositions for treating medical disorders. In certain embodiments, compositions and methods relate to reducing or inhibiting a the onset or development of a viral disorder.... | 08/19/2010 |
| 20100210532 | USE OF NEUROPEPTIDE SF, ALONE OR IN COMBINATION WITH GLP-2, AS A THERAPEUTIC AGENT The present invention is directed to the use of the peptide compound Ser-Gln-Ala-Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative d... | 08/19/2010 |
| 20100210552 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, t... | 08/19/2010 |
| 20100209386 | AGONIST AND ANTAGONIST PEPTIDES OF CARCINOEMBRYONIC ANTIGEN (CEA) The invention provides a peptide comprising an agonist of a MHC Class I binding native sequence having amino acid substitution(s) and enhanced immunogenicity compared to the native sequence. The invention also provides methods comprising the administration of the peptid... | 08/19/2010 |
| 20100209467 | TDF-RELATED COMPOUNDS AND ANALOGS THEREOF, ANALOGS AND BIOACTIVE FRAGMENTS The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules, which act as functional modulators of ... | 08/19/2010 |
| 20100209493 | HLA-A2 Tumor Associated Antigen Peptides and Compositions A peptide or composition comprising at least one HLA-A2 epi tope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.... | 08/19/2010 |
| 20100210562 | USE OF IL-1 RECEPTOR PEPTIDE, ALONE OR IN COMBINATION WITH D-ALA-GLN-OCTADECYL ESTER, AS A THERAPEUTIC AGENT The present invention is directed to the use of the peptide compound Lys-lle-Cys-lle-Arg-lle-Gln-lle-Ser-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, ... | 08/19/2010 |
| 20100209499 | Solid Oral Dosage Form Containing an Enhancer The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug an... | 08/19/2010 |
| 20100210561 | USE OF PEPTIDE AS A THERAPEUTIC AGENT The present invention is directed to the use of the peptide compound Tyr-D-Cys(tBu)-Gly-Phe-Leu-Thr(tBu)-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, ... | 08/19/2010 |
| 20100209443 | Vaccine for the Prevention of Breast Cancer Relapse The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical r... | 08/19/2010 |
| 20100204138 | USE OF TRP6-TRIPTORELIN AND D-LEU6-LEUPROLIDE AS THERAPEUTIC AGENTS The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative disea... | 08/12/2010 |
| 20100204146 | Treatment of Oestrogen Dependant Conditions in Pre-menopausal Women The present invention relates to a method for treating and/or preventing ovarian cycle disturbance, prolonged un-opposed secretion of estrogens, and/or ovarian follicular cyst formation in pre-menopausal women with functional ovaries when treated with steroid sulfatase ... | 08/12/2010 |
| 20100204139 | USE OF GONADORELIN AS A THERAPEUTIC AGENT The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative disea... | 08/12/2010 |
| 20100204137 | THE USE OF SUBSTANCES FOR THE TREATMENT OF LOSS OF EYESIGHT IN HUMANS WITH GLAUCOMA AND OTHER DEGENERATIVE EYE DISEASES Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of β-amyloid (Aβ) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.... | 08/12/2010 |
| 20100204140 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT The present invention is directed to the use of the peptide compound Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegener... | 08/12/2010 |
